Intra-Articular Program (Professional): Material, Protocol, Training

Joint comfort injections are growing faster than their documentation. This playbook supplies the missing professional layer: characterized material, protocols, training. material documentation — a characterized EV program with protocols and training is the missing professional layer.

01 · The problem

Joint comfort injections are among the fastest-growing clinic services — and among the thinnest on material documentation: operators cannot verify particle characterization, enrichment, or endotoxin status of what they administer. A standardized program — characterized EVs, joint-specific protocols, operator training, cold-chain logging — converts a service trend into a defensible clinic offering.

02 · Scientific rationale

The MSC-EV osteoarthritis literature is the most developed joint-relevant body: Renumber the reference list so in-text [2] = MISEV2018 and [3] = the OA review; verify PMC9413347 resolves before publishing.otective-associated signalling in OA models [3]. TONGNIAN's translation is protocol-level: joint-specific administration documents, characterized batches with enrichment checks, and comfort-program framing only — the literature informs the protocol; it is not quoted as product efficacy.

03 · Program documentation

Joint-program protocol structures follow TONGNIAN's internal professional-use documentation and network-clinic session records [6].

Method anchors: [1] EV biology and cargo [2] MISEV2018 characterization [3] category evidence (review or registered study) [4] formulation and handling guidance [5] national measurement guideline (2026 No. 17) [6] internal protocol and case documentation.

04 · Product architecture

05 · Process & QC

EV material runs on the fully enclosed 0.5–5 L micro-batch line with low-shear handling qualified at process validation [4]. QC panel design follows MISEV2018 [2] and the national measurement guideline (2026 No. 17, TONGNIAN a drafting organization) [5].

Fig. 1 — The joint program stack: material, protocol, training.

06 · Regulatory pathway: EU & US first

State the channel explicitly: professional human clinics; veterinary placement evaluated case by case. Material chain (DMF Type II 044197, INCI 41316) documented; finished programs follow destination-market professional-use rules. No consumer therapeutic claims. The published OA literature is cited as scientific background for the research area — never as product-efficacy evidence [3].

07 · Expected outcomes

• Standardized material: characterized batches with enrichment and sterility checks per batch.
• Defensible protocol: training and documentation the clinic's counsel can review.
• Comfort-program framing that stays inside professional-use boundaries.

No claims are made beyond the destination-market framing — authority comes from documentation and batch measurement.

08 · Commercial framework

Sample kits in 3–5 days; pilot from 500 units; production from 2,000 units; standard lead 15 workdays — all indicative, quoted per request. White-label runs through the OBM program.

Request a quote · Line fact-sheet

References

1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
2. Engineering of MSC-derived exosomes: a promising cell-free therapy for osteoarthritis. PMC9413347.
3. Théry C, et al. MISEV2018. J Extracell Vesicles. 2018;7(1):1535750.
4. Guideline for Exosome Particle Size and Concentration Measurement (2026 No. 17) — TONGNIAN, drafting organization.
5. TONGNIAN network clinics. Anonymized internal protocol and case documentation (partner access under NDA).